Clinical trials: Psychotic Disorder
- Condition Psychotic Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Safety and Tolerability of Iloperidone
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
- Trial name
- NCT01495169
- Testing
- iloperidone (oral tablet)
- Where
- 10 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Acute Psychotic Symptoms
Quality Project to Evaluate and Validate the FAST-O Rating Scale
The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.
- Trial name
- FAST-O (NCT00913731)
- Where
- 5 sites in Sweden
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Schizophrenia
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
It's a prospective, non-interventional, observational Post-marketing Surveillance..
- Trial name
- NCT04432688
- Testing
- Lurasidone HCl
- Where
- 7 sites in China
- Volunteers
- 3,192 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
CAFE Comparison of Atypicals in First Episode of Psychosis
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day)…
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Trial name
- NCT00034892
- Testing
- Olanzapine, risperidone
- Where
- 26 sites in United States, Canada
- Sponsor
- AstraZeneca
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia, Bipolar Disorders
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
'Real life' retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.
- Conditions
- Schizophrenia, Bipolar Disorders, Major Depressive Disorders
- Trial name
- NCT01377896
- Volunteers
- 221 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents.
- Trial name
- NCT00051298
- Testing
- Olanzapine
- Where
- 25 sites in United States, Russia
- Volunteers
- 107 people
- Sponsor
- Eli Lilly and Company
Anxiety Disorders, Childhood Mental Disorder
Family-Focused CBT Skills App and Standard Self Help Options for Childhood Anxiety
Anxiety disorders are among the most common psychological disorders, with prevalent onset in childhood and adolescence. While cognitive behavioral therapy (CBT) is considered the first-line treatment for pediatric anxiety…
- Conditions
- Anxiety Disorders, Childhood Mental Disorder, Anxiety
- Trial name
- NCT03269370
- Testing
- Anchors Away, Parent Enhanced Anchors Away, Self-Help E-Book
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Kansas City Center for Anxiety Treatment, P.A.
Schizophrenia, Autism-Related Irritability
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
- Trial name
- NCT07424404
- Testing
- KarXT, KarX-EC
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
- Trial name
- NCT03817502
- Testing
- Cariprazine
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Gedeon Richter Plc.
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc